| Autor: |
Savès M; INSERM Unité 330, 33076 Bordeaux Cedex, France., Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le Moing V, Rivière C, Chêne G, Leport C |
| Jazyk: |
angličtina |
| Zdroj: |
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2000 Dec; Vol. 44 (12), pp. 3451-5. |
| DOI: |
10.1128/AAC.44.12.3451-3455.2000 |
| Abstrakt: |
In a cohort of 1,047 human immunodeficiency virus type 1-infected patients started on protease inhibitors (PIs), the incidence of severe hepatic cytolysis (alanine aminotransferase concentration five times or more above the upper limit of the normal level >/= 5N) was 5% patient-years after a mean follow-up of 5 months. Only positivity for hepatitis C virus antibodies (hazard ratio [HR], 7. 95; P < 10(-3)) or hepatitis B virus surface antigen (HR, 6.67; P < 10(-3)) was associated with severe cytolysis. Before starting patients on PIs, assessment of liver enzyme levels and viral coinfections is necessary. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
